How sermorelin works
Growth-hormone-releasing hormone (GHRH) is made in the brain and tells the pituitary gland to release growth hormone in pulses. Sermorelin mimics the active part of GHRH. Because the pituitary still controls the release, supporters argue it is gentler than taking growth hormone directly. That is a reasonable hypothesis, not a proven clinical advantage.
Its FDA history
A sermorelin product called Geref was approved for diagnosing and treating growth-hormone deficiency in children. The manufacturer discontinued it, and in 2013 FDA determined it had not been withdrawn for reasons of safety or effectiveness. No sermorelin product is currently marketed as FDA-approved. A compounded preparation does not inherit the old product’s approval.
What adult studies show
Small studies in older adults found that sermorelin can raise growth hormone and IGF-1 levels, with mixed and modest effects on body composition and wellbeing. There are no large, modern trials showing that sermorelin slows aging, improves sleep or builds muscle in healthy adults.
Side effects and who should not use it
Commonly reported effects are injection-site reactions, flushing and headache. Because it raises growth hormone and IGF-1, it is generally avoided in people with active cancer, and it needs care in people with diabetes or thyroid problems. Your clinician reviews your history and may order blood tests.
How it compares
Sermorelin and tesamorelin act on the same receptor; ipamorelin works through a different one. See tesamorelin vs sermorelin and CJC-1295 and ipamorelin explained.